Sutinat Capsules — Sunitinib 50 mg (28 Capsules) Natco
Sutinat 50 mg (Sunitinib) is a multi-targeted antitumor drug belonging to the class of tyrosine kinase inhibitors. It possesses the unique ability to block multiple receptors involved in tumor growth, pathological angiogenesis (the formation of new blood vessels that feed the tumor), and cancer metastasis. Sutinat acts on VEGFR, PDGFR, KIT, and RET receptors, providing a powerful therapeutic effect for various types of solid tumors.
Manufacturer: NATCO Pharma Ltd. Sutinat is a high-quality generic of the original drug Sutent. NATCO's production is certified according to international standards, which guarantees patients a high degree of active substance purification and stable efficacy at a significantly more affordable cost.
Key Features:
- ✅ Multi-targeted Action: Simultaneously inhibits key tumor cell survival pathways, making it difficult for resistance to develop.
- ✅ Anti-angiogenic Effect: "Starves" the tumor by blocking the growth of blood vessels that supply it.
- ✅ Golden Standard: Included in international treatment protocols for metastatic renal cancer as one of the most effective first-line drugs.
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 18.04.2026
Similar products
What Customers Say
No reviews yet
Your review can be the first!